- Vaccitech plc VACC announced Topline Interim Data from the Phase 1b/2 HPV001 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
- “This preliminary data is an encouraging step in the right direction and we look forward to seeing the final data in early 2024,” said Bill Enright, CEO of Vaccitech.
- Data from the first 58 enrolled women who reached their 6-month timepoint in the placebo-controlled HPV001 study were reviewed internally and the study is continuing as planned to the primary endpoint of 12 months.
- Also read: Vaccitech’s vaccine induced sustained reductions in hepatitis B-associated antigens.
- Immunogenicity results showed high responses, defined as an average of greater than 1,000 spotting units per million peripheral blood mononuclear cells in an ELISPOT assay, specifically to antigens E1, E2 and E6.
- VTP-200 was generally well tolerated, with no grade 3 product-related adverse events and no product-related SAEs.
- These preliminary data will be presented orally at the upcoming International Papillomavirus Conference in Washington DC, taking place April 17-21, 2023.
- Price promotion: VACC shares are down 4.35% to $2.86 on Monday’s most recent check.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
